By Gina Shaw
As of November 2024, there were 10 approved biosimilars on the market for adalimumab (Humira, AbbVie)—by far the most biosimilar competitors for any originator biologic.
Although all 10 have, over time, garnered FDA approval for every indication granted to Humira (including rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, juvenile idiopathic arthritis, ankylosing spondylitis and